Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain
Monoamine modulators showed no clear difference in leaving the study early: for any reason compared with placebo (low certainty).
1 finding from 1 review
Change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Compliance with treatment · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Nausea · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Weight: clinically important change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Weight: clinically important change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Change in BMI · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain
Topiramate showed no clear difference in leaving the study early: for any reason compared with placebo or no treatment (low certainty).
1 finding from 1 review
Compliance with treatment · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Nausea · people with schizophrenia with antipsychotic‐induced weight gain
Topiramate showed no clear difference in reports of nausea compared with placebo or no treatment (low certainty).
1 finding from 1 review
Weight: clinically important change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Weight Average endpoint/change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain
It is very uncertain whether metformin changes leaving the study early: for any reason compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Compliance with treatment · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Nausea · people with schizophrenia with antipsychotic‐induced weight gain
Metformin showed no clear difference in reports of nausea compared with placebo or no treatment (low certainty).
1 finding from 1 review
Weight: clinically important change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Relapse · schizophrenia
Maintenance treatment with antipsychotic drugs leads to lower relapse: 7 to 12 months compared with placebo/no treatment (high certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · schizophrenia
Maintenance treatment with antipsychotic drugs leads to lower leaving the study early: due to any reason (acceptability of… compared with placebo/no treatment (high certainty).
1 finding from 1 review